ONI BIOPHARMA ANNOUNCES ITS LISTING ON ALTERNEXT PARIS ONI BioPharma will be the first US company to list on Alternext Paris PARIS, France, and ALACHUA, Florida, USA (

BIOPHARMA ANNOUNCES ITS LISTING

BioPharma will be the first US company

list on Alternext Paris

France, and ALACHUA, Florida, USA (December 10, 2008) - Oragenics, Inc. d/b/a ONI

BioPharma Inc. (Alternext US1: "ONI"), an American

biopharmaceutical company that has developed broad-based technologies in oral

care, antibiotics, diagnostics and weight control, announced today its

additional listing on Alternext Paris. This new listing will make ONI

the first US-based company to have its shares traded on Alternext Paris,

beginning December 15, 2008.

Alternext Paris listing is an integral part of the ambitious commercial strategy

it has implemented. In particular, ONI has now begun sales in the United States

its first probiotic that helps maintain dental and oral health, designed for the

general consumer market.

Alternext Paris listing demonstrates ONI's confidence in the success of the

launching of EvoraPlustm

and its willingness to be seen as a major and long-term player through the

future marketing of its other products in the United States and

the Information Document published by ONI in connection with its listing on

Alternext Paris may be obtained free of charge from ONI at 13700 Progress Blvd.,

Alachua, Florida 32615, U.S.A. and from its Listing Sponsor, Bryan, Garnier

& Co Ltd, at 36 Queen Street, London EC4R 1BN, United Kingdom, and at 33,

avenue de Wagram, 75017 Paris, France, and on the websites of ONI

(www.onibiopharma.com) and Alternext Paris (www.alternext.com).

Identification codes of

ONI's shares on Alternext Paris:

Inc. (d/b/a ONI BioPharma Inc.) is a biopharmaceutical company with a pipeline

of unique proprietary technologies, some of which are being commercialized. The

Company also has a number of products in discovery, preclinical and clinical

development, with a concentration in the main therapeutic area of infectious

diseases, diagnostics, and oral health. The Company has developed platform

technologies with respect to its products, thereby creating a pipeline of future

products, which the Company expects to develop.

BIOPHARMA is listed on Alternext US (Ticker : ONI) and on Alternext Paris

(Ticker : ALONI), exchanges of the NYSE Euronext group.

Harbor Statement Under the Private Securities Litigation Reform Act of

1995: This press release includes forward-looking statements that reflect ONI

BioPharma's current views with respect to future events and financial

performance. These forward-looking statements are based on management's beliefs

and assumptions and information currently available. The words "believe,"

"expect," "anticipate," "intend," "estimate," "project" and similar expressions

that do not relate solely to historical matters identify forward-looking

statements. Investors should be cautious in relying on forward-looking

statements because they are subject to a variety of risks, uncertainties, and

other factors that could cause actual results to differ materially from those

expressed in any such forward-looking statements. We expressly disclaim any

responsibility to update forward-looking statements and draw the attention of

investors to the risk factors described in the Information

press release does not constitute the offering of any securities for sale. The

Company's securities may not be offered or sold absent registration under

applicable securities laws or an exemption from registration. Any public

offering of the securities of the Company will be made by means of a prospectus

that will contain detailed information about the offering and the